Combining copanlisib with rituximab significantly extends progression-free survival (PFS) in patients with indolent non-Hodgkin lymphoma, with an acceptable safety profile, according to results of the phase 3 CHRONOS-3 trial.
“To our knowledge, copanlisib [Aliqopa, Bayer] is the first PI3K inhibitor to be safely combined with rituximab and the first to show broad superior efficacy in combination with rituximab in patients with indolent non-Hodgkin lymphoma across subtypes,” according